<i>Notes From the Field</i> : Severe Illnesses After Self-Injection of Botulinum Toxin Purchased Online — New York, Texas, and Wisconsin, 2025

Cosmetic botulinum neurotoxin (BoNT) can be used to temporarily diminish facial wrinkles (1); however, injection for this purpose occasionally results in localized paralytic effects, even when BoNT that is approved by the Food and Drug Administration (FDA) and purchased from authorized sources is administered by licensed and trained medical professionals. Rarely, improperly procured or administered BoNT can lead to severe illness. During May-June 2025, hospital clinicians and health departments in New York, Texas, and Wisconsin each alerted CDC about a person in their jurisdiction who experienced severe illness after self-injecting cosmetic BoNT that was purchased online.* None of the three patients met their state's requirements for purchasing or administering BoNT; no link was reported among the patients. This report describes the patients' characteristics, treatment, and outcomes. This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.<sup>†</sup>.

Authors

Publication Details

Journal
MMWR Morbidity and Mortality Weekly Report
Published
2025-11-26
DOI
https://doi.org/10.15585/mmwr.mm7438a1
Primary Topic
Botulinum Toxin and Related Neurological Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Notes From the Field : Severe Illnesses After Self-Injection of Botulinum Toxin Purchased Online — New York, Texas, and Wisconsin, 2025

Joel Ackelsberg, Michelle Chang, E. W. TAYLOR, Suzanne Gibbons-Burgener et al.
MMWR Morbidity and Mortality Weekly Report
Botulinum Toxin and Related Neurological Disorders
article

Notes From the Field : Severe Illnesses After Self-Injection of Botulinum Toxin Purchased Online — New York, Texas, and Wisconsin, 2025

Joel Ackelsberg, Michelle Chang, E. W. TAYLOR, Suzanne Gibbons-Burgener, Jennifer R. Cope, O.A. Smith, Sandra Peña, Liz Lamere, Quoc Phung Than, Robert Breazu, Divya Pillendla, Ryan J. Wozniak, Pilar Zaibaq
article en

Abstract

Cosmetic botulinum neurotoxin (BoNT) can be used to temporarily diminish facial wrinkles (1); however, injection for this purpose occasionally results in localized paralytic effects, even when BoNT that is approved by the Food and Drug Administration (FDA) and purchased from authorized sources is administered by licensed and trained medical professionals. Rarely, improperly procured or administered BoNT can lead to severe illness. During May-June 2025, hospital clinicians and health departments in New York, Texas, and Wisconsin each alerted CDC about a person in their jurisdiction who experienced severe illness after self-injecting cosmetic BoNT that was purchased online.* None of the three patients met their state's requirements for purchasing or administering BoNT; no link was reported among the patients. This report describes the patients' characteristics, treatment, and outcomes. This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.<sup>†</sup>.

MMWR Morbidity and Mortality Weekly ReportVol. 74(38)
U.S. Department of State, New York City Department of Health and Mental Hygiene, Centers for Disease Control and Prevention
Openalex Percentile: Top 49%
Botulinum Toxin and Related Neurological Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.